Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep enables CAR-T trafficking in solid tumors

<< Previous

Bullboard Posts

Next >>

Comment by ENEMENEMYNEMOon Mar 28, 2024 9:25pm

105 Views

Post# 35959573

RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumors

Sure why not have this POS company start another study!!!.... take a guess how many Trials Onc has done with Pela in the last 18 years....hint ...none of them lead to anything marketable for our benefit or to any significant improvement in health outcomes...

<< Previous

Bullboard Posts

Next >>

Fobi AI responds to cease trade order, filing delay “disappointing”